# Valsartan and Amlodipine in Blood Pressure Management: Fixed-Dose vs. Free Drug Therapy

Study · id `cardio:ct-nct06487949` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06487949](<https://clinicaltrials.gov/study/NCT06487949>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06487949

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

## Technical summary

Registry record NCT06487949. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-01 (actual); primary completion 2023-10-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 114 participants (enrolled count; ClinicalTrials.gov record NCT06487949, source copy `cardio:ctgov-nct06487949-2024-07-05`, retrieved 2026-10-26)
- Started: 2022-12-01 (actual) (ClinicalTrials.gov record NCT06487949, source copy `cardio:ctgov-nct06487949-2024-07-05`, retrieved 2026-10-26)
- Primary completion: 2023-10-01 (actual) (ClinicalTrials.gov record NCT06487949, source copy `cardio:ctgov-nct06487949-2024-07-05`, retrieved 2026-10-26)
- Completion: 2023-12-01 (actual) (ClinicalTrials.gov record NCT06487949, source copy `cardio:ctgov-nct06487949-2024-07-05`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT06487949, source copy `cardio:ctgov-nct06487949-2024-07-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06487949-2024-07-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Valsartan and Amlodipine in Blood Pressure Management: Fixed-Dose vs. Free Drug Therapy
- Condition: Hypertension
- Intervention (Drug): valsartan-amlodipine 80/5 mg FDC
- Intervention (Drug): valsartan 80 mg and amlodipine 5 mg as free combination
- Lead sponsor: Shiraz University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shiraz University of Medical Sciences (`cardio:org-shiraz-university-of-medical-sciences`)

## Provenance

Content hash: a80f1af7777e28f8ed7c1d8602f80bc51adb6f564a6252e7d0c437c9f022db73
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
